Page Title
Drug Development Pipeline
VX-561 (deutivacaftor)
Status
Phase TwoTherapeutic Approach
Restore CFTR Function
VX-561 is an altered form of the potentiator ivacaftor (Kalydeco®). Potentiators are drugs that facilitate the opening of the chloride channel on the cell surface to allow chloride and sodium (salt) to move in and out of the cell. VX-561, or deuterated ivacaftor, may be more stable in the body than regular ivacaftor, which would allow it to be taken once a day.
Status
A phase 2 study was conducted to test the safety and effectiveness of VX-561 in adults with CF who have a CFTR gating mutation.
VX-561 is also being tested in combination with two correctors, VX-121 and tezacaftor.
Sponsor
This program is sponsored by Vertex Pharmaceuticals. It is being conducted within the Therapeutics Development Network.
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.
Learn More